Comparative Pharmacology
Head-to-head clinical analysis: AMBIEN versus NOLUDAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBIEN versus NOLUDAR.
AMBIEN vs NOLUDAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA. Binds selectively to the alpha-1 subunit, producing sedative, hypnotic, and anxiolytic effects.
Barbiturate that enhances GABA-A receptor activity by prolonging chloride channel opening, leading to CNS depression.
5-10 mg orally once daily at bedtime, maximum 10 mg/day.
250-500 mg orally at bedtime, with a maximum dose of 1000 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours (range 1.4–4.5 hours). In elderly patients, half-life may be prolonged to about 2.9 hours. In patients with hepatic cirrhosis, half-life is significantly increased (up to 9.8 hours).
25-35 hours
Primarily renal excretion: approximately 56% of the dose is recovered in urine as metabolites (including 5% unchanged drug). Fecal excretion accounts for about 34% of the dose. Small amounts are excreted in bile.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic